De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Seres Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
Seres Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 38.4% en 56.5% per jaar. De winst per aandeel zal naar verwachting groeien met 48.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -313% zijn.
Belangrijke informatie
38.4%
Groei van de winst
48.8%
Groei van de winst per aandeel
Biotechs winstgroei | 28.6% |
Inkomstengroei | 56.5% |
Toekomstig rendement op eigen vermogen | -313.0% |
Dekking van analisten | Good |
Laatst bijgewerkt | 12 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Sep 23Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth
Jul 13Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth
May 08Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Seres Therapeutics: What The Market Is Missing
Aug 19Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M
Aug 03Seres Therapeutics: The Good And The Challenging
Jul 12Seres Therapeutics stock slips on $100M stock offering
Jun 30Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?
Jun 16Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens
Jun 09Seres Therapeutics Is Playing A Long Game
Mar 06Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt
Dec 27Seres Therapeutics Molecular Data On SER-109 Looks Good
Oct 04Seres Therapeutics: Here We Go Again
Sep 09Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 74 | -67 | N/A | -134 | 5 |
12/31/2025 | 11 | -109 | N/A | -97 | 7 |
12/31/2024 | 22 | -102 | N/A | 42 | 7 |
6/30/2024 | 0 | -162 | -185 | -182 | N/A |
3/31/2024 | 127 | -83 | -80 | -76 | N/A |
12/31/2023 | 126 | -114 | -125 | -117 | N/A |
9/30/2023 | 127 | -141 | -133 | -123 | N/A |
6/30/2023 | 130 | -153 | -133 | -123 | N/A |
3/31/2023 | 5 | -265 | -250 | -239 | N/A |
12/31/2022 | 7 | -250 | -239 | -229 | N/A |
9/30/2022 | 13 | -231 | -236 | -228 | N/A |
6/30/2022 | 137 | -103 | -51 | -40 | N/A |
3/31/2022 | 141 | -87 | -41 | -30 | N/A |
12/31/2021 | 145 | -66 | -3 | 7 | N/A |
9/30/2021 | 155 | -34 | 32 | 41 | N/A |
6/30/2021 | 30 | -132 | -117 | -113 | N/A |
3/31/2021 | 31 | -105 | -101 | -99 | N/A |
12/31/2020 | 33 | -89 | -94 | -94 | N/A |
9/30/2020 | 23 | -90 | -90 | -90 | N/A |
6/30/2020 | 29 | -76 | -83 | -82 | N/A |
3/31/2020 | 35 | -66 | -69 | -68 | N/A |
12/31/2019 | 35 | -70 | -78 | -77 | N/A |
9/30/2019 | 38 | -73 | -50 | -50 | N/A |
6/30/2019 | 40 | -78 | -56 | -55 | N/A |
3/31/2019 | 32 | -95 | -70 | -68 | N/A |
12/31/2018 | 28 | -99 | -65 | -63 | N/A |
9/30/2018 | 21 | -107 | -99 | -96 | N/A |
6/30/2018 | 35 | -92 | -79 | -77 | N/A |
3/31/2018 | 33 | -92 | N/A | -77 | N/A |
12/31/2017 | 32 | -89 | N/A | -76 | N/A |
9/30/2017 | 32 | -86 | N/A | -76 | N/A |
6/30/2017 | 22 | -97 | N/A | -83 | N/A |
3/31/2017 | 22 | -97 | N/A | -83 | N/A |
12/31/2016 | 22 | -92 | N/A | 44 | N/A |
9/30/2016 | 19 | -86 | N/A | 53 | N/A |
6/30/2016 | 6 | -82 | N/A | 53 | N/A |
3/31/2016 | 3 | -67 | N/A | 69 | N/A |
12/31/2015 | N/A | -55 | N/A | -41 | N/A |
9/30/2015 | N/A | -44 | N/A | -33 | N/A |
6/30/2015 | N/A | -34 | N/A | -25 | N/A |
3/31/2015 | N/A | -24 | N/A | -17 | N/A |
12/31/2014 | N/A | -18 | N/A | -10 | N/A |
9/30/2014 | N/A | -12 | N/A | -8 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat MCRB de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat MCRB de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat MCRB de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van MCRB ( 56.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van MCRB ( 56.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat MCRB binnen 3 jaar verliesgevend zal zijn.